Triple-negative breast cancer molecular subtyping and treatment progress

被引：1529
作者：
Yin, Li [1 ,2 ,3 ,4 ]
Duan, Jiang-Jie [1 ,2 ,3 ,4 ]
Bian, Xiu-Wu [2 ,3 ,4 ]
Yu, Shi-cang [1 ,2 ,3 ,4 ]
机构：
[1] Army Med Univ, Third Mil Med Univ, Dept Stem Cell & Regenerat Med, Southwest Hosp, Chongqing 400038, Peoples R China
[2] Army Med Univ, Third Mil Med Univ, Inst Pathol, Southwest Hosp, Chongqing 400038, Peoples R China
[3] Army Med Univ, Third Mil Med Univ, Southwest Canc Ctr, Southwest Hosp, Chongqing 400038, Peoples R China
[4] Minist Educ, Key Lab Canc Immunopathol, Chongqing 400038, Peoples R China
来源：
BREAST CANCER RESEARCH | 2020年 / 22卷 / 01期
基金：
中国国家自然科学基金;
关键词：
Triple-negative breast cancer; Molecular subtype; Therapeutic target; Therapeutic regimen; BASAL-LIKE SUBTYPE; ADJUVANT CHEMOTHERAPY; NEOADJUVANT PACLITAXEL; CLINICAL-FEATURES; PHASE-II; IDENTIFICATION; EXPRESSION; SURVIVAL; OUTCOMES; PATHWAY;
D O I：
10.1186/s13058-020-01296-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Triple-negative breast cancer (TNBC), a specific subtype of breast cancer that does not express estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth factor receptor 2 (HER-2), has clinical features that include high invasiveness, high metastatic potential, proneness to relapse, and poor prognosis. Because TNBC tumors lack ER, PR, and HER2 expression, they are not sensitive to endocrine therapy or HER2 treatment, and standardized TNBC treatment regimens are still lacking. Therefore, development of new TNBC treatment strategies has become an urgent clinical need. By summarizing existing treatment regimens, therapeutic drugs, and their efficacy for different TNBC subtypes and reviewing some new preclinical studies and targeted treatment regimens for TNBC, this paper aims to provide new ideas for TNBC treatment.
引用
收藏
页数：13
相关论文
共 82 条
[1]  
Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0
[2]   Subtyping of Triple-Negative Breast Cancer: Implications for Therapy [J].
Abramson, Vandana G. ;
Lehmann, Brian D. ;
Ballinger, Tarah J. ;
Pietenpol, Jennifer A. .
CANCER, 2015, 121 (01) :8-16
[3]  
[Anonymous], 2017, Cancer Discov, V7, pOF10, DOI 10.1158/2159-8290.CD-NB2017-053
[4]  
[Anonymous], 2013, Breast Cancer Facts Figures 2013-2014
[5]   Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR plus or Quadruple Negative Disease [J].
Barton, Valerie N. ;
D'Amato, Nicholas C. ;
Gordon, Michael A. ;
Christenson, Jessica L. ;
Elias, Anthony ;
Richer, Jennifer K. .
HORMONES & CANCER, 2015, 6 (5-6) :206-213
[6]   Identification of Markers of Taxane Sensitivity Using Proteomic and Genomic Analyses of Breast Tumors from Patients Receiving Neoadjuvant Paclitaxel and Radiation [J].
Bauer, Joshua A. ;
Chakravarthy, A. Bapsi ;
Rosenbluth, Jennifer M. ;
Mi, Deming ;
Seeley, Erin H. ;
Granja-Ingram, Nara De Matos ;
Olivares, Maria G. ;
Kelley, Mark C. ;
Mayer, Ingrid A. ;
Meszoely, Ingrid M. ;
Means-Powell, Julie A. ;
Johnson, Kimberly N. ;
Tsai, Chiaojung Jillian ;
Ayers, Gregory D. ;
Sanders, Melinda E. ;
Schneider, Robert J. ;
Formenti, Silvia C. ;
Caprioli, Richard M. ;
Pietenpol, Jennifer A. .
CLINICAL CANCER RESEARCH, 2010, 16 (02) :681-690
[7]   DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapy [J].
Bernier, Cynthia ;
Soliman, Ahmed ;
Gravel, Michel ;
Dankner, Matthew ;
Savage, Paul ;
Petrecca, Kevin ;
Park, Morag ;
Siegel, Peter M. ;
Shore, Gordon C. ;
Roulston, Anne .
ANTI-CANCER DRUGS, 2018, 29 (08) :774-785
[8]   Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers [J].
Bertucci, Francois ;
Finetti, Pascal ;
Cervera, Nathalie ;
Charafe-Jauffret, Emmanuelle ;
Mamessier, Emilie ;
Adelaide, Jose ;
Debono, Stephane ;
Houvenaeghel, Gilles ;
Maraninchi, Dominique ;
Viens, Patrice ;
Charpin, Colette ;
Jacquemier, Jocelyne ;
Birnbaum, Daniel .
CANCER RESEARCH, 2006, 66 (09) :4636-4644
[9]   Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer:: 10-year follow-up results of The French Adjuvant Study Group 05 randomized trial [J].
Bonneterre, J ;
Roché, H ;
Kerbrat, P ;
Brémond, A ;
Fumoleau, P ;
Namer, M ;
Goudier, MJ ;
Schraub, S ;
Fargeot, P ;
Chapelle-Marcillac, I .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (12) :2686-2693
[10]   Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer [J].
Burstein, Matthew D. ;
Tsimelzon, Anna ;
Poage, Graham M. ;
Coyington, Kyle R. ;
Contreras, Alejandro ;
Fuqua, Suzanne A. W. ;
Sayage, Michelle I. ;
Osborne, C. Kent ;
Hilsenbeck, Susan G. ;
Chang, Jenny C. ;
Mills, Gordon B. ;
Lau, Ching C. ;
Brown, Powel H. .
CLINICAL CANCER RESEARCH, 2015, 21 (07) :1688-1698
123456789